Literature DB >> 3009368

Impact of tumor control on survival in carcinoma of the lung treated with irradiation.

C A Perez, M Bauer, S Edelstein, B W Gillespie, R Birch.   

Abstract

The long-term results in tumor response, intrathoracic tumor control and survival are reported in patients with medically inoperable or unresectable non-oat cell and small cell carcinoma of the lung. In 376 patients with stages T1-3, NO-2 carcinoma of the lung tumors, accessioned to a Radiation Therapy Oncology Group (RTOG) randomized study to evaluate different doses of irradiation, a higher complete response rate (24%), intrathoracic tumor control (67%) and three year survival (15%) was observed with 6000 cGy, compared with lower doses of irradiation (4000 or 5000 cGy). Increased survival was noted in patients with complete tumor response. Three year survival in complete responders was 23%, in partial responders, 10%, and in patients with stable disease, 5%. Patients treated with 6000 cGy had an overall intrathoracic failure rate of 33% at 3 years, compared with 42% for those treated with 5000 cGy, 44% for patients receiving 4000 cGy with split course, and 52% for those treated with 4000 cGy continuous course (p = 0.02). Patients surviving 6 or 12 months exhibited a statistically significant increased survival when the intrathoracic tumor was controlled. Patients treated with 5000-6000 cGy, showing tumor control, had a three year survival of 22%, versus 10%, if they had intrathoracic failure (p = 0.05). In patients treated with 4000 cGy (split or continuous), the respective survival was 20% and 10%, if the intrathoracic tumor was controlled (p = 0.001). In patients surviving 12 months after treatment with 5000-6000 cGy, on whom the intrathoracic tumor was controlled, the median survival was 29 months, in contrast to 18 months, if they developed intrathoracic failure (p = 0.05). In patients treated with 4000 cGy, the median survival was 23 months with control and 18 months without control of the intrathoracic tumor [corrected] (p = 0.008). In another RTOG study for patients with more advanced tumors (T4 or N3), those with local tumor control at 12 months had a three year survival rate of 25%, compared with 5% for those with thoracic failures. These differences are statistically significant (p = 0.006). Higher doses of irradiation yield a greater proportion of complete response, higher intrathoracic tumor control and better survival in non-oat cell medically inoperable or unresectable carcinoma of the lung.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1986        PMID: 3009368     DOI: 10.1016/0360-3016(86)90061-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  31 in total

1.  Therapy monitoring using dynamic MRI: analysis of lung motion and intrathoracic tumor mobility before and after radiotherapy.

Authors:  Christian Plathow; Holger Hof; Sabine Kuhn; Michael Puderbach; Sebastian Ley; Juergen Biederer; Claus D Claussen; Peter E Huber; Juergen Schaefer; Siegfried Tuengerthal; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2006-04-21       Impact factor: 5.315

2.  [Prevention and therapy of acute radiation injuries of the skin and mucosa. I. Results of a German multicenter questionnaire].

Authors:  J S Zimmermann; R Wilhelm; P Niehoff; R Schneider; G Kovács; B Kimmig
Journal:  Strahlenther Onkol       Date:  1998-03       Impact factor: 3.621

3.  Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy.

Authors:  Salma K Jabbour; Sinae Kim; Syed A Haider; Xiaoting Xu; Alson Wu; Sujani Surakanti; Joseph Aisner; John Langenfeld; Ning J Yue; Bruce G Haffty; Wei Zou
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-15       Impact factor: 7.038

4.  Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma.

Authors:  Mitchell Machtay; Rebecca Paulus; Jennifer Moughan; Ritsuko Komaki; J Effrey Bradley; Hak Choy; Kathy Albain; Benjamin Movsas; William T Sause; Walter J Curran
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

5.  Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123.

Authors:  William Small; Jennifer L James; Timothy D Moore; Dan J Fintel; Stephen T Lutz; Benjamin Movsas; Mohan Suntharalingam; Yolanda I Garces; Robert Ivker; John Moulder; Stephanie Pugh; Lawrence B Berk
Journal:  Am J Clin Oncol       Date:  2018-04       Impact factor: 2.339

6.  Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry.

Authors:  Pierre Truntzer; Delphine Antoni; Nicola Santelmo; Catherine Schumacher; Pierre-Emmanuel Falcoz; Elisabeth Quoix; Gilbert Massard; Georges Noël
Journal:  Rep Pract Oncol Radiother       Date:  2016-05-05

7.  Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.

Authors:  Stephanie Markovina; Fenghai Duan; Bradley S Snyder; Barry A Siegel; Mitchell Machtay; Jeffrey D Bradley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-11-01       Impact factor: 7.038

Review 8.  Radiotherapy in the management of non-small-cell lung cancer.

Authors:  A Bezjak; D Payne
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

9.  The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.

Authors:  Li Wang; Candace R Correa; Lujun Zhao; James Hayman; Gregory P Kalemkerian; Susan Lyons; Kemp Cease; Dean Brenner; Feng-Ming Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-17       Impact factor: 7.038

Review 10.  Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer.

Authors:  Josephine Feliciano; Steven Feigenberg; Minesh Mehta
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.